Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА, Россия) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020)

Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА, Россия) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020)

Автор: Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Балахонова Т.В., Гуревич В.С., Зелвеян П.А., Мураталиев Т.М., Мырзахметова Г.Ш., Суджаева О.А., Шек А.Б., Азизов В.А., Горнякова Н.Б., Качковский М.А., Малышев П.П., Покровский С.Н., Соколов А.А., Сумароков А.Б., Обрезан А.Г., Шапошник И.И., Анциферов М.Б., Аншелес А.А., Аронов Д.М., Ахмеджанов Н.М., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галстян Г.Р., Галявич А.С., Драпкина О.М., Дупляков Д.В., Ергин С.Я., Карпов Р.С., Карпов Ю.А., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачва Е.Д., Недогода С.В., Олейников В.Э., Рагино Ю.И., Скибицкий В.В., Смоленская О.Г., Халимов Ю.Ш., Чазова И.Е., Филиппов А.Е.

Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal

Рубрика: Клинические рекомендации

Статья в выпуске: 2, 2020 года.

Бесплатный доступ

Отказ от ответственности. Рекомендации ЕАК/НОА отражают точку зрения ЕАК и НОА и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК и НОА не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК/НОА и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК/НОА при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее Рекомендации ЕАК/НОА никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК/НОА не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.Члены Рабочей группы подтвердили отсутствие финансовой поддержки/ конфликта интересов. В случае сообщения о наличии конфликта интересов член(ы) Рабочей группы был(и) исключен(ы) из обсуждения разделов, связанных с областью конфликта интересов.

Еще

Дислипидемия, атеросклероз, холестерин, триглицериды, гиполипидемическая терапия

Короткий адрес: https://sciup.org/143173310

IDR: 143173310   |   DOI: 10.38109/2225-1685-2020-2-6-29

Список литературы Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА, Россия) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020)

  • Стратегия развития здравоохранения в Российской Федерации на период до 2025 года. Указ президента Российской Федерации от 06 июня 2019 г. №254. Москва, 2019.
  • Россия в цифрах 2019. Краткий статистический сборник. М.: Росстат. 2019.
  • Ежов М.В., Сергиенко И.В., Аронов Д.М., et al. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Атеросклероз и дислипидемии. 2017. Т. 3. С. 5-22.
  • Piepoli M.F., Hoes A.W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016. 37(29): 2315-2381. DOI: 10.1093/eurheartj/ehw106
  • Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019. DOI: 10.1093/eurheartj/ehz455
  • Langsted A., Nordestgaard B.G. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology. 2019. 51(2): 131-141.
  • DOI: 10.1016/j.pathol.2018.09.062
  • Farukhi Z., Mora S. The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering. Circulation. 2018. 137(1): 20-23.
  • DOI: 10.1161/CIRCULATIONAHA.117.031857
  • Langsted A., Nordestgaard B.G. Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals with and without Diabetes: 58 434 Individuals from the Copenhagen General Population Study. Clin Chem. 2010. 57(3): 482-489.
  • DOI: 10.1373/clinchem.2010.157164
  • Meijboom W.B., Meijs M.F., Schuijf J.D., et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol. 2008. 52(25): 2135- 2144.
  • DOI: 10.1016/j.jacc.2008.08.058
  • Agatston A.S., Janowitz W.R., Hildner F.J., et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990. 15(4): 827-832.
  • DOI: 10.1016/0735-1097(90)90282-t
  • Serrano C.V., de Mattos F.R., Pitta F.G., et al. Association between Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios and Coronary Artery Calcification Score among Asymptomatic Patients: Data from a Cross-Sectional Study. Mediators Inflamm. 2019. 2019: 1-8.
  • DOI: 10.1155/2019/6513847
  • Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis. 2012. 223(1): 1-68.
  • DOI: 10.1016/j.atherosclerosis.2012.05.007
  • Mortensen M.B., Falk E., Li D., et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification. JACC: Cardiovascular Imaging. 2018. 11(2): 221-230.
  • DOI: 10.1016/j.jcmg.2017.01.029
  • McDermott M.M., Kramer C.M., Tian L., et al. Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events. JACC: Cardiovascular Imaging. 2017. 10(9): 1003-1012.
  • DOI: 10.1016/j.jcmg.2016.08.012
  • Sillesen H., Sartori S., Sandholt B., et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. European Heart Journal - Cardiovascular Imaging. 2017. 19(9): 1042-1050.
  • DOI: 10.1093/ehjci/jex239
  • Perrone-Filardi P., Achenbach S., Mohlenkamp S., et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology. Eur Heart J. 2010. 32(16): 1986-1993.
  • DOI: 10.1093/eurheartj/ehq235
  • Den Ruijter H.M., Peters S.A.E., Anderson T.J., et al. Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction. JAMA. 2012. 308(8): 796-803.
  • DOI: 10.1001/jama.2012.9630
  • Stein J.H., Korcarz C.E., Hurst R.T., et al. Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine. Journal of the American Society of Echocardiography. 2008. 21(2): 93-111.
  • DOI: 10.1016/j.echo.2007.11.011
  • Vlachopoulos C., Xaplanteris P., Aboyans V., et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. Atherosclerosis. 2015. 241(2): 507-532.
  • DOI: 10.1016/j.atherosclerosis.2015.05.007
  • Robinson J.G., Williams K.J., Gidding S., et al. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc. 2018. 7(20).
  • DOI: 10.1161/jaha.118.009778
  • Kamstrup P.R. Lipoprotein(a): the common, likely causal, yet elusive risk factor for cardiovascular disease. J Lipid Res. 2017. 58(9): 1731-1732.
  • DOI: 10.1194/jlr.c079111
  • Tsimikas S., Fazio S., Ferdinand K.C., et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol. 2018. 71(2): 177-192.
  • DOI: 10.1016/j.jacc.2017.11.014
  • Eckel R.H., Jakicic J.M., Ard J.D., et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation. 2013. 129(25 suppl 2): S76-S99.
  • DOI: 10.1161/01.cir.0000437740.48606.d1
  • de Lorgeril M., Salen P., Martin J.-L., et al. Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction. Circulation. 1999. 99(6): 779-785.
  • DOI: 10.1161/01.cir.99.6.779
  • Estruch R., Ros E., Salas-Salvado J., et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018. 378(25): e34.
  • DOI: 10.1056/NEJMoa1800389
  • Mozaffarian D., Lemaitre R.N., King I.B., et al. Plasma Phospholipid LongChain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults. Ann Intern Med. 2013. 158(7): 515-525. 10.7326/0003- 4819-158-7-201304020-00003
  • DOI: 10.7326/0003-4819-158-7-201304020-00003
  • Lu Z., Kou W., Du B., et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. Am J Cardiol. 2008. 101(12): 1689- 1693.
  • DOI: 10.1016/j.amjcard.2008.02.056
  • Li Y., Jiang L., Jia Z., et al. A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia. PLoS One. 2014. 9(6): e98611.
  • DOI: 10.1371/journal.pone.0098611
  • Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013.
  • DOI: 10.1002/14651858.cd004816.pub5
  • Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. The Lancet. 2003. 361(9364): 1149-1158.
  • DOI: 10.1016/s0140-6736(03)12948-0
  • Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet. 2004. 364(9435): 685- 696.
  • DOI: 10.1016/s0140-6736(04)16895-5
  • Schwartz G.G. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial. JAMA. 2001. 285(13): 1711.
  • DOI: 10.1001/jama.285.13.1711
  • Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. 350(15): 1495-1504.
  • DOI: 10.1056/NEJMoa040583
  • Patti G., Pasceri V., Colonna G., et al. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention. J Am Coll Cardiol. 2007. 49(12): 1272-1278.
  • DOI: 10.1016/j.jacc.2007.02.025
  • Shepherd J., Kastelein J.J., Bittner V., et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008. 51(15): 1448-1454.
  • DOI: 10.1016/j.jacc.2007.11.072
  • Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002. 18(4): 220-228.
  • DOI: 10.1185/030079902125000787
  • Amarenco P., Bogousslavsky J., Callahan A., 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006. 355(6): 549-559.
  • DOI: 10.1056/NEJMoa061894
  • Newman C.B., Palmer G., Silbershatz H., et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003. 92(6): 670-676.
  • DOI: 10.1016/s0002-9149(03)00820-8
  • Group S.C. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010. 160(5): 785-794.e710.
  • DOI: 10.1016/j.ahj.2010.08.012
  • Abifadel M., Varret M., Rabès J.-P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003. 34(2): 154-156.
  • DOI: 10.1038/ng1161
  • Norata G.D., Tibolla G., Catapano A.L. Targeting PCSK9 for Hypercholesterolemia. Annual Review of Pharmacology and Toxicology. 2014. 54(1): 273-293.
  • DOI: 10.1146/annurev-pharmtox-011613-140025
  • Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015. 372(25): 2387-2397.
  • DOI: 10.1056/NEJMoa1410489
  • Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017. 376(18): 1713-1722.
  • DOI: 10.1056/nejmoa1615664
  • Giugliano R.P., Pedersen T.R., Park J.-G., et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. The Lancet. 2017. 390(10106): 1962-1971.
  • DOI: 10.1016/s0140-6736(17)32290-0
  • Boekholdt S.M., Hovingh G.K., Mora S., et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. J Am Coll Cardiol. 2014. 64(5): 485-494.
  • DOI: 10.1016/j.jacc.2014.02.615
  • Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018. 379(22): 2097-2107.
  • DOI: 10.1056/NEJMoa1801174
  • Castelli W.P. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol. 1992. 70(19): H3-H9.
  • DOI: 10.1016/0002-9149(92)91083-g
  • Barter P., Gotto A.M., LaRosa J.C., et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine. 2007. 357(13): 1301-1310.
  • DOI: 10.1056/nejmoa064278
  • Carey V.J., Bishop L., Laranjo N., et al. Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control. Am J Cardiol. 2010. 106(6): 757-763.
  • DOI: 10.1016/j.amjcard.2010.05.002
  • Aguiar C., Alegria E., Bonadonna R.C., et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate- statin combination therapy. Atherosclerosis Supplements. 2015. 19: 1-12.
  • DOI: 10.1016/s1567-5688(15)30001-5
  • National Cholesterol Education Program Expert Panel on Detection E., Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002. 106(25): 3143-3421. doi
  • Hegele R.A., Ginsberg H.N., Chapman M.J., et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014. 2(8): 655-666.
  • DOI: 10.1016/S2213-8587(13)70191-8
  • Ghandehari H., Kamal-Bahl S., Wong N.D. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008. 156(1): 112-119.
  • DOI: 10.1016/j.ahj.2008.03.005
  • Gitt A.K., Drexel H., Feely J., et al. Persistent lipid abnormalities in statintreated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2011. 19(2): 221-230.
  • DOI: 10.1177/1741826711400545
  • Yuan G., Al-Shali K.Z., Hegele R.A. Hypertriglyceridemia: its etiology, effects and treatment. Can Med Assoc J. 2007. 176(8): 1113-1120.
  • DOI: 10.1503/cmaj.060963
  • Reaven G.M., Chen Y.D., Jeppesen J., et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. Journal of Clinical Investigation. 1993. 92(1): 141-146.
  • DOI: 10.1172/jci116541
  • Ridker P.M., Rifai N., Cook N.R., et al. Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. JAMA. 2005. 294(3): 326.
  • DOI: 10.1001/jama.294.3.326
  • Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine. 2010. 362(17): 1563-1574.
  • DOI: 10.1056/nejmoa1001282
  • Bhatt D.L., Steg P.G., Miller M., et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019. 380(1): 11-22.
  • DOI: 10.1056/nejmoa1812792
  • Fruchart J.C., Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs of Today. 2006. 42(1): 39.
  • DOI: 10.1358/dot.2006.42.1.963528
  • Keating G.M., Croom K.F. Fenofibrate. Drugs. 2007. 67(1): 121-153.
  • DOI: 10.2165/00003495-200767010-00013
  • Cholesterol Treatment Trialists C., Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010. 376(9753): 1670-1681.
  • DOI: 10.1016/S0140-6736(10)61350-5
  • Mark L., Dani G., Fazekas Ö., et al. Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes. Curr Med Res Opin. 2007. 23(7): 1541- 1548.
  • DOI: 10.1185/030079907x199817
  • Kim N.H., Han K.H., Choi J., et al. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019. 366: l5125.
  • DOI: 10.1136/bmj.l5125
  • Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. The Lancet. 2001. 357(9260): 905-910.
  • DOI: 10.1016/s0140-6736(00)04209-4
  • Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. 2005. 366(9500): 1849-1861.
  • DOI: 10.1016/s0140-6736(05)67667-2
  • Kovacs C.S., Seshiah V., Swallow R., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism. 2013. 16(2): 147-158.
  • DOI: 10.1111/dom.12188
  • Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015. 373(22): 2117-2128.
  • DOI: 10.1056/nejmoa1504720
  • Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016. 375(4): 311-322.
  • DOI: 10.1056/nejmoa1603827
  • Marso S.P., Bain S.C., Consoli A., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. 375(19): 1834-1844.
  • DOI: 10.1056/NEJMoa1607141
  • Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019.
  • DOI: 10.1093/eurheartj/ehz486
  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998. 352(9131): 854-865.
  • DOI: 10.1016/s0140-6736(98)07037-8
  • Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013. 34(45): 3478-3490a.
  • DOI: 10.1093/eurheartj/eht273
  • Rosengren A. Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? Eur Heart J. 2012. 33(5): 562-563.
  • DOI: 10.1093/eurheartj/ehr364
  • Prospective Studies C., Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007. 370(9602): 1829-1839.
  • DOI: 10.1016/S0140-6736(07)61778-4
  • Second Joint Task Force of E. Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J. 1998. 19(10): 1434-1503.
  • DOI: 10.1053/euhj.1998.1243
  • Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation. 2006. 113(6): 791-798.
  • DOI: 10.1161/circulationaha.105.548206
  • Berry J.D., Dyer A., Cai X., et al. Lifetime Risks of Cardiovascular Disease. New England Journal of Medicine. 2012. 366(4): 321-329.
  • DOI: 10.1056/nejmoa1012848
  • Giang K.W., Björck L., Novak M., et al. Stroke and coronary heart disease: predictive power of standard risk factors into old age-longterm cumulative risk study among men in Gothenburg, Sweden. Eur Heart J. 2013. 34(14): 1068-1074.
  • DOI: 10.1093/eurheartj/ehs458
  • Wilhelmsen L., Svärdsudd K., Eriksson H., et al. Factors associated with reaching 90 years of age: a study of men born in 1913 in Gothenburg, Sweden. J Intern Med. 2010. 269(4): 441-451.
  • DOI: 10.1111/j.1365-2796.2010.02331.x
  • Reiner Ž. Primary Prevention of Cardiovascular Disease with Statins in the Elderly. Curr Atheroscler Rep. 2014. 16(7).
  • DOI: 10.1007/s11883-014-0420-6
  • Savarese G., Gotto A.M., Paolillo S., et al. Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease. J Am Coll Cardiol. 2013. 62(22): 2090-2099.
  • DOI: 10.1016/j.jacc.2013.07.069
  • Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The Lancet. 2002. 360(9346): 1623-1630.
  • DOI: 10.1016/s0140-6736(02)11600-x
  • Deedwania P., Stone P.H., Bairey Merz C.N., et al. Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. Circulation. 2007. 115(6): 700-707.
  • DOI: 10.1161/circulationaha.106.654756
  • Miettinen T.A., Pyorä lä K., Olsson A.G., et al. Cholesterol-Lowering ̈ Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris. Circulation. 1997. 96(12): 4211-4218.
  • DOI: 10.1161/01.cir.96.12.4211
  • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002. 360(9326): 7-22.
  • DOI: 10.1016/s0140-6736(02)09327-3
  • Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011. 377(9784): 2181-2192.
  • DOI: 10.1016/S0140-6736(11)60739-3
  • Tonelli M., Wanner C. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Ann Intern Med. 2014. 160(3): 182-189.
  • DOI: 10.7326/m13-2453
  • Naci H., Brugts J., Ades T. Comparative Tolerability and Harms of Individual Statins. Circulation: Cardiovascular Quality and Outcomes. 2013. 6(4): 390-399.
  • DOI: 10.1161/circoutcomes.111.000071
  • Bruckert E., Hayem G., Dejager S., et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients -The PRIMO Study. Cardiovascular Drugs and Therapy. 2005. 19(6): 403-414.
  • DOI: 10.1007/s10557-005-5686-z
  • Davidson M.H., Clark J.A., Glass L.M., et al. Statin Safety: An Appraisal from the Adverse Event Reporting System. Am J Cardiol. 2006. 97(8): S32-S43.
  • DOI: 10.1016/j.amjcard.2005.12.008
  • Marcum Z.A., Vande Griend J.P., Linnebur S.A. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012. 10(4): 264-271.
  • DOI: 10.1016/j.amjopharm.2012.05.002
  • Chalasani N., Aljadhey H., Kesterson J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004. 126(5): 1287-1292.
  • DOI: 10.1053/j.gastro.2004.02.015
  • Vuppalanchi R., Chalasani N., Teal E. Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes. Am J Med Sci. 2005. 329(2): 62-65.
  • DOI: 10.1097/00000441-200502000-00002
  • Dongiovanni P., Petta S., Mannisto V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015. 63(3): 705-712.
  • DOI: 10.1016/j.jhep.2015.05.006
  • Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol. 2006. 97(8A): 52C-60C.
  • DOI: 10.1016/j.amjcard.2005.12.010
  • Li Y.H., Ueng K.C., Jeng J.S., et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc. 2017. 116(4): 217-248.
  • DOI: 10.1016/j.jfma.2016.11.013
Еще
Статья научная
SciUp 2024 © 2024 ©